

APAS® PHARMAQC EXHIBITED AT PHARMACEUTICAL CONFERENCE

New data demonstrates APAS® PharmaQC can benefit environmental monitoring processes

Adelaide, Australia, 5 October 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT or the Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the Company's APAS® PharmaQC technology was presented at the Parenteral Drug Association annual Pharmaceutical Microbiology conference (**PDA Micro**) held in Washington DC, United States (2-4 October 2023).

Key Points:

- **PDA Micro 2023: Annual conference focussed on future of pharmaceutical microbiology industry**
- **First time APAS® PharmaQC presented at pharmaceutical microbiology conference**
- **New APAS® PharmaQC performance data released**
- **Preliminary results demonstrate a high level of performance that supports the use of APAS® PharmaQC for routine environmental monitoring testing in sterile manufacturing**

The annual PDA Micro conference is one of the leading conferences for pharmaceutical microbiologists, bringing together professionals from around the world to discuss the opportunities and challenges facing the industry. At this year's conference, the Company presented APAS® PharmaQC on the Clever Culture Systems booth, providing the opportunity for delegates to meet with the Company and observe demonstrations of the technology. This was the first time the Company has exhibited APAS® PharmaQC commercially at a pharmaceutical microbiology industry event.



During the conference, the Company released new APAS® PharmaQC performance data from its pilot primary validation studies. The data collected assessed key performance metrics for the product, to comply with pharmacopeial guidelines and is an important consideration for customers when assessing the technology.

A high level of precision within and across multiple instruments was observed, in addition to a high degree of accuracy and linearity of counting for typical model organisms. These data build on the body of evidence which is supported by the pilot secondary validation study performed at AstraZeneca (see ASX release [First APAS® PharmaQC Performance Data](#)) which

collectively provide evidence and confidence that the use of APAS® PharmaQC for routine environmental monitoring testing in sterile manufacturing is supported.

The White Paper presented at the conference can be read in full on the LBT website: [Click here](#)

LBT CEO and Managing Director, Mr Brent Barnes said:

“With growing performance data for our APAS® PharmaQC product, it’s important that we establish a commercial presence and create awareness with microbiology pharmaceutical industry stakeholders. PDA Micro has been a fantastic conference to exhibit APAS® for the first time, receiving positive feedback on our performance data in addition to liking our established and reliable hardware platform evidenced from the clinical market. We remain extremely positive in our outlook and believe this segment to be an important growth driver for the Company.”

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company’s second product, the Automated Plate Assessment System (APAS® Independence) uses LBT’s intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT’s wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

| |
|---|
| LBT Innovations |
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com |